Market Intel: Opportunities for Medtech In Mental Health (Part 1) – Transcranial Magnetic Stimulation
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. In this first part of a two-part series focusing on mental health tech, Medtech Insight focuses on transcranial magnetic stimulation systems used to treat severe anxiety and depression, among other indications. Part two will focus on the skyrocketing use of telehealth, apps and light therapy.
You may also be interested in...
Execs On The Move: Management, Marketing Changes At Medtronic And Brainsway; New CEO At Tactile Medical
A new CMO and VP is selected at Medtronic’s Coronary and Structural Heart division; Brainsway, a developer of neuromodulation products, decides on a VP for global marketing; Tactile Medical, offering treatments for lymphedema and venous ulcers; announced a new CEO; and more.
US FDA used its de novo review pathway to approve Brainsway Ltd.’s Brainsway Deep Transcranial Magnetic Stimulation System to treat obsessive compulsive disorder.
Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.